If you have been reading about HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-09. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
=== Myopathies with cores === 'Core myopathies' such as multicore myopathy and central core disease are characterized by sharply-demarcated areas devoid of oxidative enzymes NADH, SDH, and COX, in muscle fibres.
The goal of this is to restrict supply and therefore raise prices, particularly in response to unexpected drops in demand, a health scare, or international market volatility. In 2018, this was 4.59% of the CAP budget. The benefits of many of these subsidies go to the parties in the food supply chains with most bargaining power, which is usually supermarkets. The Agricultural Unfair Trading Practices Directive 2019 article 3 prohibits practices such as late payments by buyers of food to suppliers, cancellations at short notice, unilateral alteration of terms, threats of commercial retaliation, and payments by suppliers to the buyers (i.e. from farmers to supermarkets) for stocking, adverts, marketing or staff. These rules limit supermarkets' abuse of a dominant position but do not ensure subsidies reach farm communities. The Food Safety Regulation 2002 article 14 requires that food is not place on the market if it is 'injurious to health' or is 'unfit for human consumption', but there is no requirement that supermarkets or others eliminate harmful packaging such as plastic. The third main part, administered by the European Agricultural Fund for Rural Development, is 'rural development' payments, which are 24.4% of the CAP budget. Following the 'Europe 2020 Strategy by promoting sustainable rural development', payments are made for knowledge transfer, advice, asset investment, and business development aid. Priorities may include improving water and energy use.
In April 2023, Lula met with union leaders and took part in the Brazil-Spain Business Forum in Madrid. On 26 April, Lula, alongside several of his cabinet ministers, met with Spanish prime minister Pedro Sánchez at the Moncloa Palace, where he signed two different deals regarding education and work areas, which includes facilitating student exchange programmes between universities in both countries, expanding cooperation between in higher education and adopting regulations for IT companies Later on that day, Lula, Rosângela and FM Mauro Vieira met with King Felipe VI at the Royal Palace of Madrid. In March 2023, Lula received Sánchez in Brasília ahead of the 2024 G20 Rio de Janeiro summit to discuss trade relations between Brazil and Spain including the EU-Mercosur Association Agreement as well the reform of world institutions such as the United Nations and the World Bank.
Sources: en.wikipedia.org
Ketone bodies can be used as fuels, yielding 22 ATP and 2 GTP molecules per acetoacetate molecule when oxidized in the mitochondria. Ketone bodies are transported from the liver to other tissues, where acetoacetate and beta-hydroxybutyrate can be reconverted to acetyl-CoA to produce reducing equivalents (NADH and FADH2), via the citric acid cycle. Ketone bodies cannot be used as fuel by the liver, because the liver lacks the enzyme β-ketoacyl-CoA transferase, also called thiolase. Acetoacetate in low concentrations is taken up by the liver and undergoes detoxification through the methylglyoxal pathway which ends with lactate. Acetoacetate in high concentrations is absorbed by cells other than those in the liver and enters a different pathway via 1,2-propanediol. Though the pathway follows a different series of steps requiring ATP, 1,2-propanediol can be turned into pyruvate.
The mechanical equivalence principle was first stated in its modern form by the German surgeon Julius Robert von Mayer in 1842. Mayer reached his conclusion on a voyage to the Dutch East Indies, where he found that his patients' blood was a deeper red because they were consuming less oxygen, and therefore less energy, to maintain their body temperature in the hotter climate. He discovered that heat and mechanical work were both forms of energy, and in 1845, after improving his knowledge of physics, he published a monograph that stated a quantitative relationship between them.
In Lao cuisine, Lao coriander is used extensively in traditional Lao dishes such as 'mok pa' (steamed fish in banana leaf) and several coconut milk curries that contain fish or prawns. In China dill is called colloquially, 'huíxiāng' (茴香, perfume of Hui people), or more properly 'shíluó' (莳萝/蒔蘿). It is a common filling in 'baozi', 'jiaozi' and 'xianbing' and may be used as vegetarian with rice vermicelli, or combined with either meat or eggs. Vegetarian dill baozi are a common part of a Beijing breakfast. In baozi and xianbing, it often is interchangeable with non-bulbing fennel and the term 茴香 also may refer to fennel, similarly to caraway and coriander leaf, sharing a name in Chinese as well. Dill also may be stir fried as a potherb, often with egg, in the same manner as Chinese chives. In Northern China, Beijing, Inner-Mongolia, Ningxia, Gansu, and Xinjiang, dill seeds commonly are called 'zīrán' (孜然), but also 'kūmíng' (枯茗), 'kūmíngzi' (枯茗子), 'shíluózi' (莳萝子/蒔蘿子), 'xiǎohuíxiāngzi' (小茴香子) and are used with pepper for lamb meat. In the whole of China, 'yángchuàn' (羊串) or 'yángròu chuàn' (羊肉串), lamb brochette, a speciality from Uyghurs, uses cumin and pepper. In Cantonese-speaking regions such as Hong Kong and Macau, the leaves are more colloquially known as 刁草 (diu1 cou2), a partial calque of the English 'dillweed'; 'dill' transliterated into the otherwise unrelated 刁 diu1 and 'weed' translated as 草 cou2. In Taiwan, it is also commonly used as a filling in steamed buns (baozi) and dumplings (jiaozi). In Vietnam, the use of dill in cooking is regional.
A process in which a person is given important facts about a medical procedure or treatment, a clinical trial, or genetic testing before deciding whether or not to participate. It also includes informing the patient when there is new information that may affect his or her decision to continue. Informed consent includes information about the possible risks, benefits, and limits of the procedure, treatment, trial, or genetic testing. (NCI) The process of learning the key facts about a clinical trial before deciding whether or not to participate. It is also a continuing process throughout the study to provide information for participants. To help someone decide whether or not to participate, the doctors and nurses involved in the trial explain the details of the study. (NLM) A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject's decision to participate. Informed consent is documented by means of a written, signed, and dated informed consent form. (ICH E6) Informed consent document
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.